Who
Mark E. Saad
Director
Company insider
Files Form 4 as: Director, Axsome Therapeutics; Director, Flyte Aviation; Chief Financial Officer, Cerenome.
In numbers
- Trades disclosed
- 124
- Buys
- 17
- Sells
- 3
- Bought
- $421K
- Sold
- $14.6M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 24 Jan 2006
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,429 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,429 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,429 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,429 | filing |
| 5 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,721 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,721 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K6,231 at $8.02 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M6,231 at $165.18 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $155K31,346 at $4.95 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,231 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,346 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.2M31,346 at $165.18 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,231 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,346 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K6,231 at $8.02 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M6,231 at $165.18 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $155K31,346 at $4.95 | filing |
| 31 Dec 2025filed 2 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.2M31,346 at $165.18 | filing |
| 5 Sep 2025filed 5 Sep 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,127 at $0.00 | filing |
| 5 Sep 2025filed 5 Sep 2025 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $82K9,127 at $9.00 | filing |
News
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?AXSM · fool.com · 8 Oct 2026
0 headlines in the last 90 days name Mark E. Saad; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.